SG Austria gets milestone payment

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...

Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal

Novo Nordisk and Vivtex have formalised a collaboration aimed...

Pharmaceutical and Holistic Therapies: Exploring Their Role in Effective Addiction Recovery

Addiction recovery has evolved into a multidisciplinary clinical domain...
- Advertisement -

The Economic Development Board of Singapore has paid milestone payment to SG Austria, an affiliate of Nuvilex.The milestone was paid for achieving key scientific milestones following independent scientific review of the company’s ongoing R&D projects. The payment is part of the previously announced five-year, $1.5m grant funded by the Economic Development Board of Singapore in 2008 and covers four of the company’s ongoing projects.Nuvilex president and CEO Robert Ryan said they can look forward to some of the data being released to the scientific and investor communities in the near future.

“We are also pleased to note that other, separate grant and milestone payments are on track over the next 12 months, increasing the value of our energies in Nuvilex, and in particular our affiliate SG Austria, the live-cell encapsulation platform, and the promises it holds for the scientific and medical fields,” Ryan said.

Latest stories

Related stories

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...

Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal

Novo Nordisk and Vivtex have formalised a collaboration aimed...

Pharmaceutical and Holistic Therapies: Exploring Their Role in Effective Addiction Recovery

Addiction recovery has evolved into a multidisciplinary clinical domain...

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »